title: Outcome of patients with amyloidosis after renal transplantation: a single-center experience.
abstract: OBJECTIVE
  The prognostic outcome of patients with amyloidosis who receive a kidney transplant is controversial. The aim of the study was to analyze the renal transplantation outcome of patients with amyloidosis compared to transplant recipients with other kidney diseases.
  
  
  METHODS
  Among 940 patients who had renal transplantation in our unit between 1983 and 2009, 44 patients with amyloidosis were compared regarding early and late complications and survival, retrospectively, with a control group of 41 consecutive patients with the same donor type and a matched renal transplantation date.
  
  
  RESULTS
  The groups were similar regarding demographic parameters, HLA mismatch numbers and mean follow-up period. Groups were similar regarding early and late infectious and non-infectious complications, except recurrence of the primary disease, which was more common in the amyloidosis group. As the cause of graft loss, rejection (acute or chronic) was more common in the control group; whereas primary non-functioning graft, and death with a functioning graft were more common in the amyloidosis group. Patient survival rates at 1, 5, and 10 years were 87.6%, 78.1%, and 62.3 in the amyloidosis group; and 93.2%, 82.6%, and 69.3% in the control group. Graft survival rates at 1, 5 and 10 years were 87.6%, 75.4%, 56.4% in the amyloidosis group; and 93.2%, 80.3%, and 60.6% in the control group, respectively. These values did not show any statistical difference.
  
  
  CONCLUSIONS
  The outcomes of renal transplantation in patients with amyloidosis are comparable with recipients whose primary problems are due to other kidney diseases; therefore, amyloidosis patients should be accepted as good candidates for transplantation.
authors.affiliation: Department of Nephrology, Haseki Training and Research Hospital, Istanbul - Turkey. meltem1401@yahoo.com
authors.forename: Meltem
authors.initials: M
authors.lastname: Gursu
authors.forename: Berna
authors.initials: B
authors.lastname: Yelken
authors.forename: Yasar
authors.initials: Y
authors.lastname: Caliskan
authors.forename: Rumeyza
authors.initials: R
authors.lastname: Kazancioglu
authors.forename: Halil
authors.initials: H
authors.lastname: Yazici
authors.forename: Isin
authors.initials: I
authors.lastname: Kilicaslan
authors.forename: Aydin
authors.initials: A
authors.lastname: Turkmen
authors.forename: Mehmet S
authors.initials: MS
authors.lastname: Sever
mesh_terms: D000328:Adult; D000686:Amyloidosis / Q000150:complications / Q000601:surgery*; D016009:Chi-Square Distribution; D005260:Female; D006084:Graft Rejection / Q000209:etiology / Q000401:mortality; D006085:Graft Survival; D006801:Humans; D053208:Kaplan-Meier Estimate; D007674:Kidney Diseases / Q000150:complications / Q000601:surgery*; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D014421:Turkey